EUVIMEDOpdag EUVIMED
Fallbericht

Venlafaxine deprescribing and thyroid function

Barbara J Zarowitz iD, Shaily Jain

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · 2023-06 · 43 (6) · 570-573

DOI: 10.1002/phar.2803 ↗

At a glance

Fallbericht in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, published online on 2023-04-26. Written by Barbara J Zarowitz and 1 co-authors. Institution: Peter Lamy Center on Drug Therapy and Aging, University of Maryland School of Pharmacy, Baltimore, Maryland, USA. Major MEDLINE topics: Deprescriptions, Hashimoto Disease. Cited 4 times so far (Crossref); 21 references.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Study Objective This report highlights the effects of discontinuing venlafaxine on thyroid function in an older adult with previously well‐managed Hashimoto thyroiditis and sleep apnea.

Design

Concurrent intervention. Case study.

Setting

Community‐based psychiatry practice Patient ‐ 66 year old female Intervention Over 8 months, a 66‐year‐old patient slowly reduced the venlafaxine dose. She was treated simultaneously for sleep apnea.

Measurements

Clinical data including venlafaxine and levothyroxine dosing, thyroid hormone laboratory values, subjective complaints, and objective electrocardiographic (ECG) findings were aggregated and analyzed. Main Results As venlafaxine dose was decreased over time, the patient complained of bounding heart palpitations shown to be premature ventricular contractions, and wide and narrow complex ventricular tachycardia on ECG. Thyroid‐stimulating hormone decreased from a baseline value of 0.791 uIU/mL to a nadir of 0.18 uIU/mL during venlafaxine dosage reduction from 225 mg/day to 155 mg/day. Cardiac symptoms subsided following levothyroxine dosage reduction.

Conclusions

There was a direct relationship between antidepressant dosage reduction and levothyroxine dosage requirements. Cautious monitoring is recommended during venlafaxine deprescribing in patients with pre‐existing thyroid disease.

Subjects

MeSH terms (MEDLINE)

DeprescriptionsHashimoto DiseaseFemaleHumansAgedThyroxineVenlafaxine Hydrochloride

Author keywords

SNRIdeprescribingdiscontinuationthyroid hormone

Substances

ThyroxineVenlafaxine Hydrochloride

Authors and institutions

  • Peter Lamy Center on Drug Therapy and Aging, University of Maryland School of Pharmacy, Baltimore, Maryland, USA.
  • Cairn Center, Las Vegas, Nevada, USA.

ORCID profiles: Barbara J Zarowitz

Cite

APA

Zarowitz, B. J., & Jain, S. (2023). Venlafaxine deprescribing and thyroid function. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 43(6), 570-573. https://doi.org/10.1002/phar.2803

Vancouver

Zarowitz BJ, Jain S. Venlafaxine deprescribing and thyroid function. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2023;43(6):570-573. doi:10.1002/phar.2803

BibTeX
@article{Zarowitz2023,
  author = {Zarowitz, Barbara J and Jain, Shaily},
  title = {Venlafaxine deprescribing and thyroid function},
  journal = {Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy},
  year = {2023},
  volume = {43},
  number = {6},
  pages = {570--573},
  doi = {10.1002/phar.2803}
}
Start for free →